{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:21:10Z","timestamp":1793744470241,"version":"4.6.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001190.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000}}],"reference-count":301,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001190.pub3","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T22:17:13Z","timestamp":1529446633000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":292,"title":["Donepezil for dementia due to Alzheimer's disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Jacqueline S","family":"Birks","sequence":"first","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; Botnar Research Centre, Windmill Road Oxford UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Harvey","sequence":"additional","affiliation":[{"name":"Deakin University and Private Practice; Medical School; c\/o Telepsychiatrist Online PO Box 117 North Geelong Victoria Australia 3215"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"10.1002\/14651858.CD001190.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"AD2000 Collaborative Group","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0002|cit2","unstructured":"Bentham P Gray R Hill R Sellwood E Courtney C Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 337"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0003|cit3","unstructured":"Lendon CL Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden: Abstract No 1287 2002"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0004|cit4","unstructured":"Roberts N A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000) National Research Register 2001"},{"issue":"9427","key":"10.1002\/14651858.CD001190.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(04)16533-1","article-title":"AD2000: donepezil in Alzheimer's disease","volume":"363","author":"Schneider","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0006|cit6","unstructured":"Waghray S AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease National Research Register 2000 http:\/\/www.doh.gov.uk\/nrr.htm"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0007|cit7","first-page":"A347","article-title":"Treatment of severe Alzheimer's disease with donepezil: results from a 24-week, multinational, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Black","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0008|cit8","unstructured":"Black S Li Honglang McRae T Richardson S Donepezil treatment of severe Alzheimer's disease: results from a 24-week, multinational, randomized, double-blind, placebo controlled trial Poster Presented at the Geneva Springfield Conference April 2006"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","article-title":"Donepezil preserves cognition and global function in patients with severe Alzheimer disease","volume":"69","author":"Black","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0010|cit10","unstructured":"Pfizer E2020-A001-315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD www.marc.soton.ac.uk\/Research%20Page.htm"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0011|cit11","unstructured":"Richardson S A 24 week, multicenter, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open-label extension period www.clinicaltrials.gov\/ct\/show\/NCT00096473 2004"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0012|cit12","unstructured":"Bayer AJ Rossor M Hecker J Gauthier S Burns A Petite H International Donepezil Study Group Donepezil improves functional activity in patients with Alzheimer's disease 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12-16, Glasgow, Scotland 1998 SR-HANDSRCH"},{"issue":"8","key":"10.1002\/14651858.CD001190.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gps.1746","article-title":"Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease","volume":"22","author":"Burns","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0015|cit15","unstructured":"Gauthier S Rosser M Hecker J Petite H Rogers S Mohr E Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-June 4, Toronto, Canada 1998 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0016|cit16","unstructured":"Gauthier S Rossor M Hecker J Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease Poster presentation at 5th International Geneva\/Springfield Symposium on Advances in Alzheimer Therapy"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Pratt RD Gauthier S Burns A Perdomo CA Donepezil provides long-term clinical benefits for patients with Alzheimers disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82652-4"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cns.12076","article-title":"High-dose donepezil (23 mg\/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines","volume":"19","author":"Cummings","year":"2013","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"2-3","key":"10.1002\/14651858.CD001190.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000338236","article-title":"Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine","volume":"33","author":"Doody","year":"2012","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0020|cit20","unstructured":"Doody RS Ramos H Faison W Zou H Efficacy and safety of donepezil 23 mg\/d vs. donepezil 10 mg\/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA 2011"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Farlow M Richardson S Mackell J Sun Y Long-term safety and tolerability of donepezil 23 MG in patients with moderate-to-severe Alzheimer's disease: an 18-month analysis Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France 2011","DOI":"10.1016\/j.jalz.2011.05.2242"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2377-11-57","article-title":"Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease","volume":"11","author":"Farlow","year":"2011","journal-title":"BMC Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001190.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","article-title":"Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study","volume":"32","author":"Farlow","year":"2010","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Donepezil 23 MG\/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco 2012","DOI":"10.1186\/alzrt166"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/alzrt166","article-title":"Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity","volume":"5","author":"Ferris","year":"2013","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Ferris S MacKell J Bai Z Sun Y Effect of donepezil 23 mg\/day on language function in patients with moderate-to-severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)-based patients Alzheimer's Association International Conference 2012 Vancouver, BC Canada 2012","DOI":"10.1016\/j.jalz.2012.05.1613"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/alzrt84","article-title":"Analyzing the impact of 23 mg\/day donepezil on language dysfunction in moderate to severe Alzheimer's disease","volume":"3","author":"Ferris","year":"2011","journal-title":"Alzheimer's Research & Therapy"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ane.12571","article-title":"Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease","volume":"135","author":"Han","year":"2017","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2318-13-56","article-title":"Evaluating the cognitive effects of donepezil 23 mg\/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response","volume":"13","author":"Sabbagh","year":"2013","journal-title":"BMC Geriatrics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Sabbagh M Cummings J Christensen D Doody R Farlow M MacKell J Evaluating the cognitive effects of donepezil 23 MG\/D in moderate and severe Alzheimer's disease: a patient subgroup analysis Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco 2012","DOI":"10.1186\/1471-2318-13-56"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000448214","article-title":"Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimer's disease in the Asia-Pacific region","volume":"6","author":"Sabbagh","year":"2016","journal-title":"Dementia and Geriatric Cognitive Disorders Extra"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1756-0500-5-283","article-title":"Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease","volume":"5","author":"Tariot","year":"2012","journal-title":"BMC Research Notes"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0033|cit33","unstructured":"Tariot P Yardley J Moline M Brand-Schieber E Zou H Timothy H Long-term safety and tolerability of high dose donepezil (23 mg\/day) in moderate to severe Alzheimer's disease: a 12-month open-label study Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA 2010"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0044|cit34","unstructured":"Feldman H Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 59"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001190.pub3-BIB0035|cit35","first-page":"34","article-title":"Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD)","volume":"9","author":"Feldman","year":"2002","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0034|cit36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.","volume":"51","author":"Feldman","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0036|cit37","unstructured":"Feldman H Gauthier S Hecker J Vellas B Hux M Emir B Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 285"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0037|cit38","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1212\/01.WNL.0000134663.79663.6E","article-title":"Economic evaluation of donepezil in moderate to severe Alzheimer disease","volume":"63","author":"Feldman","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0038|cit39","unstructured":"Feldman H Gauthier S Hecker J Vellas B Ieni J Xu Y Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097 2005"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82641-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0041|cit41","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 174"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0039|cit42","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 2001 613 20","DOI":"10.1212\/WNL.57.4.613"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0042|cit43","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil MSAD Study Group Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease Neurology 2000 A469"},{"issue":"6","key":"10.1002\/14651858.CD001190.pub3-BIB0043|cit44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gps.1325","article-title":"Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial","volume":"20","author":"Feldman","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0051|cit45","first-page":"34","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate-to-severe Alzheimer's disease, and impact on caregiver burden","volume":"7","author":"Gauthier","year":"2004","journal-title":"Geriatrics and Aging"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","article-title":"Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease","volume":"14","author":"Gauthier","year":"2002","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0046|cit47","unstructured":"Gauthier S Feldman H Hecker J Vellas B Emir B McGill PS Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 277"},{"issue":"6","key":"10.1002\/14651858.CD001190.pub3-BIB0047|cit48","first-page":"347","article-title":"Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease","volume":"18","author":"Gauthier","year":"2002","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0048|cit49","doi-asserted-by":"crossref","unstructured":"Gauthier S Feldman H Hecker J Vellas B Subbiah P Whalen E Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82065-5"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0049|cit50","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1016\/S0924-977X(00)80473-3","article-title":"Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease","volume":"10","author":"Gauthier","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0050|cit51","unstructured":"Gauthier S Feldman H Vellas B Subbiah P Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease Journal of the American Geriatrics Society 2000 S2"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Hecker J Foti D Gauthier S Vellas B Subbiah P Whalen E Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82066-7"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Luckmann R Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease ACP-Journal-Club 2002 59","DOI":"10.7326\/ACPJC-2002-136-2-059"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Panisset M Feldman H Gauthier S Hecker J Vellas B Subbiah P Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82648-2"},{"issue":"S2","key":"10.1002\/14651858.CD001190.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0197-4580(04)80698-5","article-title":"Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease","volume":"25","author":"Shah","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Vellas B Feldman H Gauthier S Hecker J Subbiah P Whalen E Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82647-0"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00004714-200304000-00020","article-title":"Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia","volume":"23","author":"Hegerl","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0058|cit58","first-page":"251","article-title":"Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Homma A Takeda M Imai Y Udaka F Hasegawa K Kameyama M E2020 Study Group Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan Dementia and Geriatric Cognitive Disorders 2000 299 313","DOI":"10.1159\/000017259"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Homma A Arimoto I Kaidoji K Ohbayashi T Ozawa H Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo-controlled study in Japan 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006 2006","DOI":"10.1016\/j.jalz.2006.05.1728"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","article-title":"Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial","volume":"25","author":"Homma","year":"2008","journal-title":"Geriatric Cognitive Disorders"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000203887","article-title":"Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan","volume":"27","author":"Homma","year":"2009","journal-title":"Dementia and Geritatric Congitive Disorders"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3233\/JAD-151149","article-title":"Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double-blind trial","volume":"52","author":"Homma","year":"2016","journal-title":"Journal of Alzheimer's disease"},{"issue":"14","key":"10.1002\/14651858.CD001190.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ebmh.11.3.84","article-title":"Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease","volume":"11","author":"Pelosi","year":"2008","journal-title":"Evidence-Based Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3233\/JAD-161117","article-title":"Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial","volume":"56","author":"Jia","year":"2017","journal-title":"Journal of Alzheimer's disease"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0067|cit67","unstructured":"Anon No title Eisai Inc"},{"issue":"11","key":"10.1002\/14651858.CD001190.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"The American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0069|cit69","unstructured":"Robert P Lebert F Goni S Touchon J Vincent S ARIAL Study Investigators Collaborative Group The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease Quality Research in Dementia; 19-22 November, 2000, London 2000"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0070|cit70","unstructured":"Robert PH Lebert F Goni S Touchon J ARIAL Study Investigators Collaborative Group The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC 1999 SR-HANDSRCH"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer's disease: a randomized, placebo-controlled study","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Maher-Edwards G Zvartau-Hind M Davies J Alexander K Schronen J Boswell D Effects of 6-month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild-to-moderate Alzheimer's disease Alzheimer's Association International Conference, Paris, France 2011","DOI":"10.1016\/j.jalz.2011.05.2236"},{"issue":"9","key":"10.1002\/14651858.CD001190.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/j.1468-1331.2007.01710.x","article-title":"Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study","volume":"14","author":"Korczyn","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD001190.pub3-BIB0074|cit74","first-page":"e10","article-title":"Letter to the editor","volume":"14","author":"Mazza","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD001190.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1468-1331.2006.01409.x","article-title":"Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study","volume":"13","author":"Mazza","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0076|cit76","unstructured":"Ebell M Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently? Evidence Based Practice 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0077|cit77","first-page":"A415","article-title":"Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one-year placebo-controlled functional survival study","volume":"54","author":"Mohs","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001190.pub3-BIB0078|cit78","first-page":"S46","article-title":"Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study","volume":"48","author":"Mohs","year":"2000","journal-title":"Journal of the American Geriatrics Society"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001190.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(99)80460-X","article-title":"Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study","volume":"9","author":"Mohs","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni JR Rogers SL Perdomo CA Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study Quality Research in Dementia Conference; 2000 November 19-22, London 2000","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo C 312 Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [Erratum] Neurology 2001 1942 http:\/\/www.lww.com","DOI":"10.1212\/WNL.57.10.1942-a"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0083|cit83","unstructured":"Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo CA Donepezil preserves functional status in Alzheimer's disease 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illinois 2000 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0084|cit84","unstructured":"Pratt R Mohs R Doody R Morris J Rogers S Ieni J Donepezil preserves functional status in Alzheimer's disease patients results from a 1-year prospective placebo controlled functional study Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 178"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1378\/chest.07-1446","article-title":"Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double-blind, placebo-controlled study","volume":"133","author":"Moraes","year":"2008","journal-title":"Chest"},{"issue":"S47","key":"10.1002\/14651858.CD001190.pub3-BIB0086|cit86","first-page":"368","article-title":"Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea","volume":"7","author":"Moraes","year":"2006","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/sleep\/29.2.199","article-title":"The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study","volume":"29","author":"Moraes","year":"2006","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0088|cit88","unstructured":"Friedhoff LT Ieni JR Rogers SL Pratt RD Donepezil provides long-term clinical benefits for patients with Alzheimer's Disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12-16, Glasgow, Scotland 1998 ABSTRACT REF: PW11017 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0089|cit89","unstructured":"Friedhoff LT Rogers SL Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5-8, San Diego 1997 6 7"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Rogers S Perdomo C Friedhoff L Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020 Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30-October 4, Venice 1995a SR-HANDSRCH","DOI":"10.1016\/0924-977X(95)90701-E"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Rogers SL Doody RS Pratt RD Ieni JR Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study European Neuropsychopharmacology 2000 195 203","DOI":"10.1016\/S0924-977X(00)00067-5"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0093|cit92","unstructured":"Rogers SL Friedhoff LT E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1-7, Washington DC 1994 A165"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0092|cit93","first-page":"293","article-title":"The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Rogers","year":"1996","journal-title":"Dementia"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Archives of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0095|cit95","first-page":"116","article-title":"Long-term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease","volume":"6","author":"Pratt","year":"1999","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0098|cit96","unstructured":"Rogers SL Donepezil new clinical trials support long term use Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5-8, Stockholm 2000 133"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0096|cit97","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease","volume":"158","author":"Rogers","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0097|cit98","unstructured":"Rogers SL Mohs RC Friedhoff LT Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials American Psychiatric Association 150th Annual Meeting, San Diego 1997"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil MSAD Study Investigators Group Erratum: a 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613-620)) Neurology 2001 2153","DOI":"10.1212\/WNL.57.4.613"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0101|cit101","first-page":"A100","article-title":"Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston","volume":"48","author":"Friedhoff","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0102|cit102","unstructured":"Friedhoff LT Rogers SL Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17, Vienna, Austria 1997 SR-HANDSRCH"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190.pub3-BIB0103|cit103","first-page":"S9","article-title":"Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis","volume":"4","author":"Friedhoff","year":"1997","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0109|cit104","unstructured":"Rogers SL Donepezil new clinical trials support long term use Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5-8, Stockholm 2000 133"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0104|cit105","first-page":"A217 S14.001 AR","article-title":"E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial","volume":"46","author":"Rogers","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0105|cit106","unstructured":"Rogers SL Doody R Mohs R Friedhoff T Donepezil Study Group E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30-week trial Unpublished paper 1996b"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0106|cit107","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0107|cit108","unstructured":"Rogers SL Friedhoff LT Farlow MR Doody RS Mohs R Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply] Neurology 1999 218 19"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0108|cit109","unstructured":"Rogers SL Mohs RC Friedhoff LT Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials American Psychiatric Association 150th Annual Meeting, San Diego 1997"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0110|cit110","unstructured":"Schindler R Corey-Bloom J Doody R Zhang R Ieni JR Li H Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg\/day 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004"},{"issue":"S2","key":"10.1002\/14651858.CD001190.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0197-4580(04)80657-2","article-title":"Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg\/day","volume":"25","author":"Schindler","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0113|cit112","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/archneur.62.5.825","article-title":"Erratum: efficacy of donepezil in early-stage alzheimer disease: a randomized placebo-controlled trial (Archives of Neurology (December 2004) 61 (1852-1856))","volume":"62","author":"Seltzer","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0112|cit113","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease","volume":"61","author":"Seltzer","year":"2004","journal-title":"Archives of Neurolology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0114|cit114","unstructured":"Anon No title Eisai Inc"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0115|cit115","unstructured":"Anon No title Eisai Inc"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1601-5215.2002.51022.x","article-title":"Donepezil for nursing home patients with dementia: a reinterpretation of the evidence","volume":"51","author":"Steinman","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0117|cit117","first-page":"S3","article-title":"Donepezil was well-tolerated and enhanced cognition in nursing home patients with Alzheimer's disease","volume":"47","author":"Tariot","year":"1999","journal-title":"Journal of the American Geriatrics Society"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD001190.pub3-BIB0118|cit118","first-page":"134","article-title":"Age is not a barrier to donepezil treatment of Alzheimer's disease in the long-term care setting","volume":"11","author":"Tariot","year":"1999","journal-title":"International Psychogeriatrics"},{"issue":"12","key":"10.1002\/14651858.CD001190.pub3-BIB0119|cit119","first-page":"1590","article-title":"A randomised, double-blind, placebo-controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0120|cit120","first-page":"133","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting","volume":"51","author":"Tariot","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0121|cit121","unstructured":"Tune L Tiseo P Hoffman J Perdomo C Votaw J Rogers S PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24-week study 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23-26 San Francisco 2001"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00019442-200303000-00007","article-title":"Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study","volume":"11","author":"Tune","year":"2003","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0123|cit123","unstructured":"Tune LE Tiseo PJ Hoffman JM Perdomo CA Votow JR Rogers SL Functional brain activity in Alzheimer's disease 151st Annual Meeting of the American Psychiatric Association; 1998 May 30- June 4, Toronto 1998 NR345 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Engedal K Soininen H Verhey F Waldemar G Winblad B Wimo A Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease Journal of the European College of Neuropsychopharmacology 2000 S368 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(00)80492-7"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0125|cit125","doi-asserted-by":"crossref","unstructured":"Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double-blind, randomized trial Journal of the American Geriatrics Society 2001 S131","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0126|cit126","unstructured":"Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0127|cit127","unstructured":"Soininen H Winblad B Engedal K Verhey F Waldemar G Wimo A Long term benefits of donepezil on ADLs in AD patients Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville 2000 171"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Soininen H Winblad B Engedal K Verhey F Waldemar G Wimo A Donepezil Nordic Study Group Response to donepezil is not predicted by apolipoprotein E genotype and\/or gender World Alzheimer Congress; 2000 July 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82062-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Waldemar G Winblad B Engedal K Soininen H Donepezil Nordic Study Group et al Benefits of donepezil on cognition, function and\/or neuropsychiatric symptoms in patients with Alzheimers disease over one year World Alzheimer Congress; 2000 July 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)83186-3"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0130|cit130","first-page":"A470","article-title":"Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year","volume":"54","author":"Waldemar","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0134|cit131","doi-asserted-by":"crossref","unstructured":"Wimo A Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44-54)) Dementia and Geriatric Cognitive Disorders 2003 102","DOI":"10.1159\/000066669"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0131|cit132","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000066669","article-title":"An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial","volume":"15","author":"Wimo","year":"2003","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one-year, double-blind, randomized trial World Alzheimer Congress; 2000 July 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0132|cit134","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V Haglund A Hertzman P Miceli R An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one-year, double-blind, randomized trial 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0139|cit135","unstructured":"Winblad B Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5-8, Stockholm 2000 164"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD001190.pub3-BIB0135|cit136","first-page":"138","article-title":"Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Winblad","year":"1999","journal-title":"International Psychogeriatrics"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0136|cit137","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0137|cit138","unstructured":"Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Donepezil enhances global function and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000"},{"issue":"5-6","key":"10.1002\/14651858.CD001190.pub3-BIB0138|cit139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy","volume":"21","author":"Winblad","year":"2006","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0140|cit140","unstructured":"Batsman S Minthon L Eeriksson S Kilander L Jansson-Blixt C Wetterholm A Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease IPA 12th International Congress, Stockholm, Sweden, 20-24 September 2005 2005"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0141|cit141","unstructured":"Eriksson S Winblad B Kilander L Batsman S Jansson-Blixt C Wetterholm A Efficacy of donepezil on secondary end points in a randomized, double-blind placebo-controlled study in severe Alzheimer's disease IPA 12th International Congress, Stockholm, Sweden, 20-24 September 2005 2005"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000167267","article-title":"Donepezil treatment of severe Alzheimer's disease in nursing home settings","volume":"26","author":"Jelic","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0143|cit143","unstructured":"Kilander L Winblad B Minthon L Batsman S Jansson-Blixt C Cronlund A Donepezil is well tolerated in patients with severe Alzheimer's disease IPA 12th International Congress, Stockholm, Sweden, 20-24 September 2005 2005"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11910-996-0015-x","article-title":"Donepezil in patients with severe Alzheimer's disease: double-blind parallel-group, placebo controlled study","volume":"6","author":"Marder","year":"2006","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(06)69098-3","article-title":"Donepezil for severe Alzheimer's disease","volume":"368","author":"Opie","year":"2006","journal-title":"Lancet"},{"issue":"9533","key":"10.1002\/14651858.CD001190.pub3-BIB0149|cit146","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(06)69099-5","article-title":"Donepezil for severe Alzheimer's disease - author's reply","volume":"368","author":"Winblad","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0150|cit147","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1017\/S1041610206004017","article-title":"Severe Alzheimer's disease: benefits of donepezil therapy","volume":"18","author":"Winblad","year":"2006","journal-title":"International Psychogeriatrics"},{"issue":"9156","key":"10.1002\/14651858.CD001190.pub3-BIB0146|cit148","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0147|cit149","unstructured":"Winblad B Minthon L Eriksson S Batsman S Jansoon-Blixt C Wetterholm A Efficacy of donepezil on primary end points in a randomized, double-blind placebo-controlled study in severe Alzheimer's disease IPA 12th International Congress, Stockholm, Sweden, 20-24 September 2005 2005"},{"issue":"S1","key":"10.1002\/14651858.CD001190.pub3-BIB0148|cit150","first-page":"S25","article-title":"Efficacy of donepezil on primary end points in a randomized, double-blind placebo-controlled study in severe Alzheimer's disease","volume":"18","author":"Winblad","year":"2005","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0151|cit151","unstructured":"Ames D Boada M Sakka P Triau E Turcani P Vagenas V Efficacy and tolerability of donepezil in patients with Alzheimer's disease: findings from a large multinational experience study 17th Alzheimer's Disease International Conference; 2001 October 25-27, Christchurch, New Zealand 2001 181"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0152|cit152","unstructured":"Johannsen P Barcikowska M Hasselbalch S Ihl R Karageorgiou C Nunez M AWARE Study Group Results from the pre-randomization phase of the donepezil aware study further understanding the meaning of clinical benefit 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 201"},{"issue":"S2","key":"10.1002\/14651858.CD001190.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0197-4580(04)80066-6","article-title":"Behavioral benefits with continued donepezil treatment in Alzheimer's disease patients","volume":"25","author":"Johannsen","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0155|cit155","unstructured":"Johanssen O Dautzenburg P Heun R Holub R Jakab G Kozubski W AWARE Study Group Results from the pre-randomization phase of the donepezil AWARE study: further understanding the meaning of \"clinical benefit\" 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002 Abstract No 305"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0156|cit156","unstructured":"Johanssen P Hasselbalch S Jakab G Kalisvaart CJ Kozubski W Kurz A Behavioral benefits with continued donepezil treatment in Alzheimer's disease patients 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4943(01)00187-X","article-title":"Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial","volume":"33","author":"Barak","year":"2001","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0158|cit158","doi-asserted-by":"crossref","unstructured":"Berger E Sramko CA Fr\u00f6lich L Calabrese P Donepezil provides relevant therapeutic benefits in different domains to real world patients with Alzheimer's disease The 12th ENCP Congress European Neuropsychopharmacology, London, 2000 2000 369","DOI":"10.1016\/S0924-977X(00)80494-0"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0159|cit159","doi-asserted-by":"crossref","unstructured":"Sramko CA Berger F Calabrese P Fr\u00f6lich L Tolerability and safety of donepezil in the treatment of Alzheimer's disease results from a post marketing surveillance study The 12th ENCP Congress European Neuropsychopharmacology, London, 2000 2000 368","DOI":"10.1016\/S0924-977X(00)80493-9"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0160|cit160","unstructured":"Birt AR Fay S Graham JE Rockwood K Recovery of intention as a novel effect on treating Alzheimer's disease with donepezil 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 595"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.58.3.442","article-title":"Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment","volume":"58","author":"Borroni","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0162|cit162","unstructured":"Boundy K Brodaty H Australian Donepezil Study Group Barrington M O'Leary M Short K Efficacy of donepezil in patients with Alzheimer's disease: findings from the Australian subset of a large multinational experience study Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001190.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1016\/S0924-977X(00)80490-3","article-title":"Efficacy and safety of donepezil in patients with Alzheimer's disease preliminary findings from the Australian subset of a global clinical experience study","volume":"10","author":"Brodaty","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Bullock RA Voss SE The clinical utility of donepezil: from randomized clinical trials to practice World Alzheimer Congress; 2000 July 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82083-7"},{"issue":"11","key":"10.1002\/14651858.CD001190.pub3-BIB0166|cit165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease","volume":"16","author":"Blesa","year":"2006","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0167|cit166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1185\/030079906X89685","article-title":"Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease","volume":"22","author":"Bullock","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0168|cit167","first-page":"S19","article-title":"The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week, multinational, comparative study","volume":"49","author":"Bullock","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0169|cit168","unstructured":"Bullock R Wilkinson DG Passmore P Hopker SW Smith R Potocnik FC Caregiver and physician determination of satisfaction with and ease of use of donepezil and rivastigamine treatment in Alzheimer's disease patients 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001 39"},{"issue":"6","key":"10.1002\/14651858.CD001190.pub3-BIB0165|cit169","first-page":"332","article-title":"Well tolerated, effective and inexpensive therapy of Alzheimer's dementia with donepezil","volume":"6","author":"B\u00f6ttcher-Buhler","year":"2000","journal-title":"Neurologie und Rehabilitation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0170|cit170","unstructured":"Potocnik FC Smith R Passmore P Hock C Wilkinson D Maud CM Tolerability, ease of use, and efficacy of donepezil and rivastigmine in Alzheimer's disease patients Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans 2001"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X80279","article-title":"Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0172|cit172","unstructured":"Wilkinson D Passmore P Potocnik F Maud C Hock C Donepezil compared to rivastigmine in Alzheimer's disease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"issue":"10","key":"10.1002\/14651858.CD001190.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/1099-1166(200010)15:10<887::AID-GPS212>3.0.CO;2-M","article-title":"Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice","volume":"15","author":"Cameron","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190.pub3-BIB0174|cit174","first-page":"S267","article-title":"The safety of donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease","volume":"3","author":"Clary","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0175|cit175","unstructured":"Finkel S McRae T Burt T Sertraline and donepezil demonstrate greater efficacy and similar tolerability compared to donepezil alone in non-depressed patients with Alzheimer's disease 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23-26, San Francisco 2001"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0176|cit176","first-page":"A416","article-title":"Donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease","volume":"54","author":"McRae","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0177|cit177","doi-asserted-by":"crossref","unstructured":"McRae T Griesing T Whalen E Effectiveness of donepezil on behavioural disturbances in mild to moderate Alzheimer's disease patients World Alzheimer Congress; 2000 July 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82644-5"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0178|cit178","unstructured":"McRae T Griesling T Whalen E Managing behaviour symptoms in patients with Alzheimer's disease (AD) Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville 2000 173"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0179|cit179","doi-asserted-by":"crossref","unstructured":"Cumbo E Improvement in behavioral and psychiatric symptoms (BPSD) in patients with moderate-to-severe Alzheimer's disease by current antidementia treatments Alzheimer's Association International Conference, Paris, France 2011","DOI":"10.1016\/j.jalz.2011.05.2225"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00019442-200005000-00008","article-title":"The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease","volume":"8","author":"Cummings","year":"2000","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0181|cit181","doi-asserted-by":"crossref","unstructured":"Howard R McShane R Lindesay J Ritchie C Baldwin A Barber R Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses Lancet Neurology 2015 1171 81","DOI":"10.1016\/S1474-4422(15)00258-6"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0182|cit182","first-page":"No Pagination S","article-title":"Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)","volume":"-","author":"Knapp","year":"2016","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"47","key":"10.1002\/14651858.CD001190.pub3-BIB0183|cit183","first-page":"3341","article-title":"Effects of donepezil treatment on platelets alpha and beta secretase activities in Alzheimer's disease patients","volume":"91","author":"Dong","year":"2011","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0184|cit184","unstructured":"Fillit H Hill JW Futtertman R Mastery V Sustained donepezil therapy reduces healthcare costs in Alzheimer's disease 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 192"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/S0924-977X(00)80475-7","article-title":"Donepezil for Alzheimer's disease - the Donald Study - a multicenter 24 weeks clinical trial in Germany","volume":"10","author":"Froelich","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-4943(01)00134-0","article-title":"Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents","volume":"33","author":"Fuschillo","year":"2001","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1532-5415.2004.52230_1.x","article-title":"Another advertisement for donepezil. Comments to the editor; reply Geldmacher","volume":"52","author":"Finucane","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"7","key":"10.1002\/14651858.CD001190.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","article-title":"Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease","volume":"51","author":"Geldmacher","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"845; author rep","DOI":"10.1111\/j.1532-5415.2004.52230_3.x","article-title":"Donepezil delay to nursing home placement study is flawed","volume":"52","author":"Karlawish","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"6","key":"10.1002\/14651858.CD001190.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1024-6; author","DOI":"10.1111\/j.1532-5415.2004.52277_3.x","article-title":"Delay in nursing home placement with donepezil","volume":"52","author":"Schneider","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0191|cit191","unstructured":"Ghorbani A Chitsaz A Shishegar M Akbari M Evaluation of the effect of donepezil on cerebral blood flow velocity in Alzheimer's disease Neurosciences (Riyadh, Saudi Arabia) 2010 172 6"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.57.1.94","article-title":"Donepezil therapy in clinical practice: a randomized crossover study","volume":"57","author":"Greenberg","year":"2000","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0193|cit193","unstructured":"Hampel H Berger F Froelich L Switching from other antidementive therapies to donepezil (Aricept): improvement of quality of life of Alzheimer patients in routine clinical use The International Symposium on advances in Alzheimer therapy, 2002, Geneva 2002 198"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0194|cit194","unstructured":"Hepple J A study of the effects of donepezil on non-cognitive symptoms in patients with Alzheimer's disease (AD) and the clinical characteristics of responders National Research Register 2003"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0196|cit195","unstructured":"Holmes C Non-cognitive symptoms and response to donepezil National Research Register 2000"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0195|cit196","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0197|cit197","unstructured":"Pandita-Gunawardena D Non-cognitive symptoms and response to donepezil National Research Register 2001"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0198|cit198","first-page":"185","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0199|cit199","first-page":"209","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0200|cit200","first-page":"145","article-title":"Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0201|cit201","first-page":"165","article-title":"Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0202|cit202","first-page":"233","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0203|cit203","unstructured":"Janssen LP A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention in patients with mild to moderate Alzheimer's disease ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0204|cit204","unstructured":"Kauffer D Catt K Pollock B DeKosky S Assessing the effects of donepezil in Alzheimer's patients and its impact on caregivers Journal of the American Geriatrics Society 1998 S66"},{"issue":"11","key":"10.1002\/14651858.CD001190.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/jnnp.74.11.1567","article-title":"A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease","volume":"74","author":"Kemp","year":"2003","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0206|cit206","unstructured":"Leube D Grodd W Erb M Henning W Bartels M Kircher T Task related cortical areas are differentially activated in patients with Alzheimer's disease after a ten week treatment with donezepil 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1548"},{"issue":"11","key":"10.1002\/14651858.CD001190.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0027-9684(15)31515-7","article-title":"Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study","volume":"100","author":"Lopez","year":"2008","journal-title":"Journal of the National Medical Association"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0208|cit208","unstructured":"Maltz J Eberling J Jagust W Budinger T Donepezil therapy enhances methacholine induced cutaneous vasodilation in Alzheimer's disease patients 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 318"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0209|cit209","doi-asserted-by":"crossref","unstructured":"Matthews HP Korbey J Wilkinson DG Rowden J Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic International Journal of Geriatric Psychiatry 2000 713 20","DOI":"10.1002\/1099-1166(200008)15:8<713::AID-GPS187>3.0.CO;2-I"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0210|cit210","unstructured":"McRae T Orazem J A large, community-based trial of donepezil in the treatment of Alzheimer's disease (AD) Journal of the American Geriatrics Society 1999 S63"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0211|cit211","unstructured":"McRae T Knopman D Duttagupta S Ieni J Provenzano G Donepezil delays time to nursing home placement in patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23-26, San Francisco 2001a"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0212|cit212","unstructured":"McRae T Knopman D Mastey V Ieni J Provenzano G Donepezil is strongly associated with delayed nursing home placement in patients with Alzheimer's disease Journal of Neuroscience 2001 S536"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0213|cit213","doi-asserted-by":"crossref","unstructured":"Mega MS Masterman DM O'Connor SM Barclay TR Cummings JL The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease Archives of Neurology 1999 1388 93","DOI":"10.1001\/archneur.56.11.1388"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0214|cit214","doi-asserted-by":"crossref","unstructured":"Mega MS Manese M Felix J Tran N O'Connor SM Masterman DM Laboratory of Neuroimaging and Alzheimer's disease Anterior cingulate activation occurs across cholinesterase inhibitor therapy in Alzheimer's disease 10th congress of the international psychogeriatric association, Nice, France, September 9-14, 2001 2001 S108","DOI":"10.1097\/00002093-200000001-00002"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0215|cit215","unstructured":"Mega M Dinov I Manese M Felix J O'Connor S Toga A Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer's disease 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 430"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1468-1331.2009.02816.x","article-title":"Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy","volume":"17","author":"Modrego","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0217|cit217","unstructured":"NCT00423228-BRAINz A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneous injections of a sustained-release implant of ZT 1 in patients with moderate Alzheimer's disease ClinicalTrials.gov 2007"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0218|cit218","unstructured":"Nikolova G Traykov L Efficacy of donepezil in patients with Alzheimer's disease - results of 12-week open clinical trial Acta Medica Bulgarica 2001 70 5"},{"issue":"8","key":"10.1002\/14651858.CD001190.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1388-2457(02)00110-4","article-title":"Effects of long-term donepezil therapy on rCBF of Alzheimer's patients","volume":"113","author":"Nobili","year":"2002","journal-title":"Clinical Neurophysiology"},{"issue":"2","key":"10.1002\/14651858.CD001190.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0013-7006(07)91552-3","article-title":"Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease","volume":"33","author":"Ollat","year":"2007","journal-title":"L'Enc\u00e9phale"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00002826-200207000-00004","article-title":"Donepezil versus vitamin E in Alzheimer's disease: part 2: mild versus moderate-severe Alzheimer's disease","volume":"25","author":"Onofrj","year":"2002","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00002826-200309000-00008","article-title":"The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia","volume":"26","author":"Onofrj","year":"2003","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0223|cit223","doi-asserted-by":"crossref","unstructured":"Parsa MA Poggi E Barte L Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil Journal of the European College of Neuropsychopharmacology 2000 S302 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(00)80339-9"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0224|cit224","unstructured":"Peng D Xu X Hou Q The safety and efficacy of Aricept in patients with Alzheimer disease Chinese Journal of Neurology 2002 19 21"},{"issue":"13","key":"10.1002\/14651858.CD001190.pub3-BIB0225|cit225","first-page":"170","article-title":"Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease","volume":"9","author":"Peng","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000095600","article-title":"Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up","volume":"22","author":"Requena","year":"2006","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0227|cit227","unstructured":"Richarz U Gaudig M Schaeuble B Zhang Z Cognitive outcomes of patients with Alzheimer's disease treated with galantamine or donepezil: a randomized, double-blind study European Journal of Neurology 15th Congress of the EFNS, Budapest, Hungary 2011"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0228|cit228","doi-asserted-by":"crossref","unstructured":"Rocca P Cocuzza E Marchiaro L Bogetto F Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety Progress in Neuro-psychopharmacology & Biological Psychiatry 2002 369 73","DOI":"10.1016\/S0278-5846(01)00283-4"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2377-7-26","article-title":"The Clinical Meaningfulness of Adas-Cog Changes in Alzheimer's Disease Patients Treated With Donepezil in an Open-Label Trial","volume":"7","author":"Rockwood","year":"2007","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0230|cit230","unstructured":"Rockwood K Graham J Fay S Translating from regulatory measures to patients' daily lives an analysis of Alzheimer's disease treatment with donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2034"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/gps.1675","article-title":"Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study","volume":"22","author":"Rockwood","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0232|cit232","doi-asserted-by":"crossref","unstructured":"Rodriguez G Vitali P De Leo C De Cadi F Girtler N Nobili F Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy International Symposium on advances in Alzheimer therapy, 2002, Geneva 2002 239","DOI":"10.1159\/000063576"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0233|cit233","unstructured":"Rogers SL Friedhoff LT Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease (AD) Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 September 13-17, Vienna, Austria 1997 SR-HANDSRCH"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190.pub3-BIB0234|cit234","first-page":"5175(PW11017)","article-title":"Donepezil provides long term benefits for patients with Alzheimer's disease","volume":"2","author":"Friedhoff","year":"1999","journal-title":"International Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0022-510X(97)86335-6","article-title":"Donepezil provides long-term clinical benefits for patients with Alzheimer's disease (AD)","volume":"150","author":"Rogers","year":"1997","journal-title":"International Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-977X(97)00079-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study","volume":"8","author":"Rogers","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0924-977X(95)90701-E","article-title":"Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor E2020","volume":"5","author":"Rogers","year":"1995","journal-title":"European Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0238|cit238","unstructured":"Rozzini L Bargnani C Bosio A Chia F Franzani S Leonardi R Acetylcholinesterase inhibitors are effective in real world patients with mild to moderate Alzheimer disease evidence from a large population treated with rivastigmine or donepezil 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 329"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0239|cit239","unstructured":"Rozzini L Bargnani C Bosio A Chia F Franzoni S Leonardi R Comparison of efficacy and safety of rivastigmine and donepezil in patients with mild to moderate Alzheimer disease: results from a multicentre randomised trial 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 240"},{"issue":"6","key":"10.1002\/14651858.CD001190.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF03324877","article-title":"Serum albumin level interferes with the effect of donepezil in Alzheimer's disease","volume":"20","author":"Rozzini","year":"2008","journal-title":"Aging Clinical Experimental Research"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0241|cit241","first-page":"220","article-title":"Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease","volume":"19","author":"Rozzini","year":"2007","journal-title":"Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0242|cit242","unstructured":"Salloway S A double blind randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and gastrointestinal GI tolerance in patients with mild to moderate Alzheimer's disease AD Clinical Trials.gov 2002 1 2"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/gps.1679","article-title":"A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement","volume":"22","author":"Sampson","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000102569","article-title":"Cognitive predictors of donepezil therapy response in Alzheimer disease","volume":"24","author":"Saumier","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0245|cit245","unstructured":"Shua-Haim J Smith J Amin S Shua-Haim V Comparison of combination therapy with rivastigmine Exelon and donepezil Aricept versus rivastigmine alone for treatment of Alzheimer's disease safety tolerability and clinical experience after one year of treatment a cross section study 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 292"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0246|cit246","unstructured":"Shua-Haim J Smith J Potel S A head to study of donepezil Aricept rivastigmine Exlon and galantamine Reminyl for the treatment of Alzheimer's disease safety tolerability clinical and caregiver impression after 4-5 months of treatment a prospective study 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 286"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0247|cit247","doi-asserted-by":"crossref","unstructured":"Stewart A Phillips R Dempsey G Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil International Journal of Geriatric Psychiatry 1998 445 53","DOI":"10.1002\/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.3.CO;2-5"},{"issue":"10","key":"10.1002\/14651858.CD001190.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp.2005.086074","article-title":"A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease","volume":"77","author":"Tarraga","year":"2006","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00213-006-0408-1","article-title":"Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial","volume":"187","author":"Teipel","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0250|cit250","unstructured":"Tessitore A Iavarone A Tessitore A Donepezil in the treatment of mild to moderate Alzheimer's disease: follow-up at 12 months in 40 treated patients Nuova Rivista di Neurologia 2000 183 6"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0251|cit251","doi-asserted-by":"crossref","unstructured":"Tettamanti M Casilli D Baldinetti F Apollonio I Ruffo P Nobili A Donepezil Italian Global Impact Study (DIGIS) Proceedings of the World Alzheimer Congress; 2000 July 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)83415-6"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0252|cit252","unstructured":"Galasko DR Gauthier S Bennett D Sano M Kaye J Marson D Impairment of activities of daily living in patients with amnestic mild cognitive impairment in an ADCS randomized clinical trial 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005 S15.001"},{"issue":"S2","key":"10.1002\/14651858.CD001190.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0197-4580(04)80064-2","article-title":"Donepezil and vitamin E as treatments for mild cognitive impairment","volume":"25","author":"Petersen","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"23","key":"10.1002\/14651858.CD001190.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0255|cit255","doi-asserted-by":"crossref","unstructured":"Thomas A Iacono D Bonanni L D' Andreamatteo G Onofrj M Donepezil, rivastigmine,and vitamin E in Alzheimer disease: a combined P300 event-related potentials\/neuropsychologic evaluation over 6 months Clinical Neuropharmacology 2001 31 42","DOI":"10.1097\/00002826-200101000-00007"},{"issue":"1","key":"10.1002\/14651858.CD001190.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X80279","article-title":"Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0257|cit257","unstructured":"Tsolaki M Gerothanassis D Aristotle CP Efficacy and safety of cholinesterase inhibitors a longitudinal comparative study between donepezil and rivastigmine 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2038"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0258|cit258","unstructured":"Vanmechelen E Andreasen N Minthon L Davidsson P Amici S Gallai V Effects of cholinesterase inhibitors on alzheimer disease biomarkers Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 252"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000152911","article-title":"Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.","volume":"26","author":"Wattmo","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0260|cit260","doi-asserted-by":"crossref","unstructured":"Weiner MF Martin-Cook K Foster BM Saine K Fontaine CS Svetlik DA Effects of donepezil on emotional\/behavioral symptoms in Alzheimer's disease patients Journal of Clinical Psychiatry 2000a 487 92","DOI":"10.4088\/JCP.v61n0705"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0261|cit261","unstructured":"Werber EA Klein C Rabey MJ Evaluation of cholinergic treatment in demented by p300 evoked related potentials 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 442"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0262|cit262","unstructured":"Haworth J Comparison of Aricept and galantamine (Reminyl) in Alzheimer's disease National Research Register 2000"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0263|cit263","unstructured":"O'Brien A A pilot study comparing the effect of galantamine (Reminyl) with donepezil in patients with Alzheimer's Disease National Research Register 2000"},{"issue":"10","key":"10.1002\/14651858.CD001190.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","article-title":"A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease","volume":"20","author":"Wilcock","year":"2003","journal-title":"Drugs & Aging"},{"issue":"3","key":"10.1002\/14651858.CD001190.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/156720507781077296","article-title":"Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?","volume":"4","author":"Winstein","year":"2007","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0266|cit266","unstructured":"Wyeth Research A 3-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR in outpatients with mild to moderate Alzheimer's disease with donepezil as active control ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0267|cit267","doi-asserted-by":"crossref","unstructured":"Zhang Z Yu L Gaudig M Schauble B Richarz U Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study Neuropsychiatric Disease and Treatment 2012 571 7","DOI":"10.2147\/NDT.S38747"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0268|cit268","first-page":"American Psychi","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0269|cit269","first-page":"637","article-title":"Clinical Dementia Rating (CDR)","volume":"24","author":"Berg","year":"1988","journal-title":"Psychopharm Bull"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1037\/0735-7028.8.4.464","article-title":"Quality of life, social indicators and criteria of change","volume":"8","author":"Blau","year":"1977","journal-title":"Professional Psychology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ageing\/25.2.113","article-title":"Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale","volume":"25","author":"Bucks","year":"1996","journal-title":"Age and Ageing"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD001190.pub3-BIB0272|cit272","first-page":"S1","article-title":"Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia","volume":"5","author":"Chertkow","year":"2013","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursinghome","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"Journal of Gerontology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0275|cit275","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) on behalf ofthe Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD001190.pub3-BIB0276|cit276","first-page":"545","article-title":"Measurement of quality-of-life changes in patients with Alzheimer's disease","volume":"11","author":"DeJong","year":"1989","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0277|cit277","unstructured":"CGI Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338 1976"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/S0197-4580(00)82096-5","article-title":"Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease","volume":"21","author":"Galasko","year":"2000","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0280|cit280","volume-title":"A User's Guide to General Health Questionnaire","author":"Goldberg","year":"1988"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"American Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0284|cit284","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0285|cit285","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0286|cit286","first-page":"1217","article-title":"Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS)","volume":"2","author":"Homma","year":"1991","journal-title":"Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0287|cit287","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"5","key":"10.1002\/14651858.CD001190.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ane.12386","article-title":"Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.","volume":"131","author":"Lee","year":"2015","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/002383099200500407","article-title":"The SKT neuropsychological test battery","volume":"5","author":"Overall","year":"1992","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","article-title":"Severe Impairment Battery: a neurological test for severely demented patients","volume":"51","author":"Panisset","year":"1994","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0293|cit293","first-page":"9","article-title":"Behavioral symptoms in Alzheimer\u2019s disease: phenomenology and treatment","volume":"Suppl 48","author":"Reisberg","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-017-0312-4","article-title":"The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.","volume":"9","author":"Ritchie","year":"2017","journal-title":"Alzheimers Research & Therapy"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"Pt 12","key":"10.1002\/14651858.CD001190.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awv316","article-title":"Alzheimer's disease in the 100 years since Alzheimer's death.","volume":"138","author":"Ryan","year":"2015","journal-title":"Brain"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001190.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0299|cit299","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R,Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD001190.pub3-BIB0301|cit301","first-page":"465","article-title":"Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials","volume-title":"Health Economics in Dementia","author":"Wimo","year":"1998"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001190.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:50:45Z","timestamp":1745880645000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001190.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":301,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001190.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]}}}